The rise of multidrug-resistant Acinetobacter baumannii and a concomitant decrease in antibiotic treatment options warrants a search for new classes of antibacterial agents. We have found that A. baumannii is pathogenic and lethal to the model host organism Caenorhabditis elegans and have exploited this phenomenon to develop an automated, high-throughput, high-content screening assay in liquid culture that can be used to identify novel antibiotics effective against A. baumannii. The screening assay involves coincubating C. elegans with A. baumannii in 384-well plates containing potential antibacterial compounds. At the end of the incubation period, worms are stained with a dye that stains only dead animals, and images are acquired using automated microscopy and then analyzed using an automated image analysis program. This robust assay yields a Z= factor consistently greater than 0.7. In a pilot experiment to test the efficacy of the assay, we screened a small custom library of synthetic antimicrobial peptides (AMPs) that were synthesized using publicly available sequence data and/or transcriptomic data from immune-challenged insects. We identified cecropin A and 14 other cecropin or cecropin-like peptides that were able to enhance C. elegans survival in the presence of A. baumannii. Interestingly, one particular hit, BR003-cecropin A, a cationic peptide synthesized by the mosquito Aedes aegypti, showed antibiotic activity against a panel of Gram-negative bacteria and exhibited a low MIC (5 g/ml) against A. baumannii. BR003-cecropin A causes membrane permeability in A. baumannii, which could be the underlying mechanism of its lethality.A cinetobacter baumannii is a Gram-negative, opportunistic bacterium that has recently emerged as a dangerous nosocomial pathogen (1-4). An increasing number of A. baumannii infections in patients have been detected among U.S. military service members injured in Iraq and Afghanistan (5). The genetic adaptability of A. baumannii allows it to gain resistance to a wide spectrum of commercial antibiotics, and the intrinsic presence of various efflux pumps in A. baumannii also contributes to an insensitivity to many antibiotics (6-8), resulting in very few viable treatment options for Acinetobacter infections (9-11). In addition, most of the clinical strains of A. baumannii also harbor a large antimicrobial resistance island (RI) of 86 kb that contains several beta-lactamase genes, conferring resistance to beta-lactam antibiotics (12, 13). The scarcity of antibiotics that can be used against A. baumannii infections drives the need for new kinds of antimicrobial agents (14).Empirical drug screening methods traditionally involve in vitro assays to measure the MICs for various pathogens. This is followed by in vivo testing of the drugs to measure their toxicity to eukaryotic cells (15). The disadvantage of these traditional assays is that a significant number of hit compounds show nonspecific toxicity to eukaryotic cells and are not promising as therapeutics (16). In this paper, we describ...